Scientists are increasingly focused on retatrutide, a innovative drug from Eli Lilly, as a possible breakthrough in body reduction . Distinct from many earlier approaches, retatrutide is a double -action agonist targeting equally GLP-1 and GIP, chemicals that impact satiety and blood sugar regul